BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 29/09/2025

FDA Clears SEMPREX-D Capsules for Approval

The FDA has determined that SEMPREX-D capsules, 8mg and 60mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of acrivastine and pseudoephedrine hydrochloride capsules.

Source: Federal Register — Food and Drug AdministrationOpen original release →